MedTrace Logo

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

NCT05070598 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-10-07

No results posted yet for this study

Summary

According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety, or affect the patient's completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.);

Conditions

  • HER2-positive Gastric Cancer

Interventions

DRUG

Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur

Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle

Sponsors & Collaborators

  • Shengjing Hospital

    lead OTHER

Principal Investigators

  • Caigang Liu, doctor · Shengjing Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2023-09-01
Completion
2024-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05070598 on ClinicalTrials.gov